Skip to content

Subcutaneous and Intramuscular Parental Ketamine for Treatment of Depression: Clinical Treatment Protocol

Joseph C.W. Tham, André Do, Jason Fridfinnson, Reza Rafizadeh, Jacky TP Siu, George P. Budd, Raymond W. Lam

preprint DOI: 10.31219/osf.io/ag6u7 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Clinical protocol
Intervention Racemic ketamine
Topics Depression Esketamine Ketamine
Key points The protocol proposes that subcutaneous and intramuscular racemic ketamine are clinically feasible alternatives to intravenous ketamine for treatment-resistant depression, potentially improving access to this treatment, based on the established rapid antidepressant effects of IV ketamine.

Abstract

Intravenous (IV) ketamine has been shown to have rapid antidepressant effects in individuals with treatment-resistant depression (TRD). This treatment protocol describes a clinical method for use of subcutaneous (SC) and intramuscular (IM) racemic ketamine in individuals with TRD, developed by a team at the University of British Columbia (UBC), UBC Hospital, and Vancouver General Hospital. The use of SC and IM ketamine may be more feasible in clinical settings than IV ketamine and provide better access to this novel treatment.

Citations in the library

Cited by 1

Cites 6

and 1 more in the library

Related reading

Explore topics

Depression Esketamine Ketamine

By condition and practice

Ketamine for depression